Delayed
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
64.97
USD
|
+0.02%
|
|
0.00%
|
+240.87%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
71.38
|
299.9
|
404.7
|
337.5
|
1,106
|
4,457
|
-
|
-
|
Enterprise Value (EV)
1 |
71.38
|
299.9
|
404.7
|
114.1
|
778.1
|
4,081
|
4,155
|
4,034
|
P/E ratio
|
-1.68
x
|
-9.4
x
|
-6.99
x
|
-4.25
x
|
-29.8
x
|
-49.2
x
|
-37
x
|
-29
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
41
x
|
32.1
x
|
17.3
x
|
11.2
x
|
18.8
x
|
246
x
|
221
x
|
434
x
|
EV / Revenue
|
41
x
|
32.1
x
|
17.3
x
|
3.79
x
|
13.2
x
|
226
x
|
206
x
|
393
x
|
EV / EBITDA
|
-
|
-
|
-8.22
x
|
-1.96
x
|
-17.8
x
|
-30.8
x
|
-27.3
x
|
-24.1
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-42.3
x
|
-29.6
x
|
-23.3
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-2.36%
|
-3.38%
|
-4.29%
|
Price to Book
|
-
|
-
|
-
|
1.88
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
18,588
|
23,803
|
29,220
|
45,914
|
58,002
|
68,598
|
-
|
-
|
Reference price
2 |
3.840
|
12.60
|
13.85
|
7.350
|
19.06
|
64.97
|
64.97
|
64.97
|
Announcement Date
|
3/30/20
|
3/18/21
|
3/17/22
|
3/23/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.74
|
9.335
|
23.44
|
30.06
|
58.88
|
18.08
|
20.2
|
10.26
|
EBITDA
1 |
-
|
-
|
-49.24
|
-58.25
|
-43.67
|
-132.5
|
-152.4
|
-167.7
|
EBIT
1 |
-43.57
|
-28.75
|
-49.86
|
-58.15
|
-44.25
|
-104.2
|
-122.9
|
-153.6
|
Operating Margin
|
-2,504.25%
|
-307.97%
|
-212.68%
|
-193.41%
|
-75.16%
|
-576.51%
|
-608.38%
|
-1,495.95%
|
Earnings before Tax (EBT)
1 |
-41.85
|
-27.95
|
-50.42
|
-55.43
|
-32.08
|
-91.5
|
-116.4
|
-148.7
|
Net income
1 |
-41.85
|
-27.94
|
-50.33
|
-57.76
|
-32.18
|
-97.06
|
-110.2
|
-148.8
|
Net margin
|
-2,405.29%
|
-299.3%
|
-214.7%
|
-192.13%
|
-54.66%
|
-536.81%
|
-545.47%
|
-1,449.39%
|
EPS
2 |
-2.280
|
-1.340
|
-1.980
|
-1.730
|
-0.6400
|
-1.320
|
-1.756
|
-2.243
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-96.45
|
-140.3
|
-172.9
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-533.45%
|
-694.47%
|
-1,684.04%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
3/18/21
|
3/17/22
|
3/23/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
223
|
327
|
376
|
302
|
423
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-96.5
|
-140
|
-173
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-38.5%
|
-12.7%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
3.900
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
2.25
|
2
|
2.42
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
12.44%
|
9.9%
|
23.54%
|
Announcement Date
|
3/30/20
|
3/18/21
|
3/17/22
|
3/23/23
|
3/18/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +240.87% | 4.46B | | +12.30% | 116B | | +12.15% | 106B | | -8.14% | 23.89B | | -1.69% | 21.58B | | -10.60% | 18.96B | | -41.25% | 16.96B | | -15.33% | 16.33B | | +5.80% | 14.14B | | +28.03% | 12.02B |
Bio Therapeutic Drugs
|